Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2025-04-04 Transaction in Own Shar…
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad remite detalle de las operaciones del Contrato de Liquidez comprendidas entre el 25 y el 28 de febrero de 2025.
Transaction in Own Shares Classification · 98% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. The title is 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and the content details the operations conducted under a previously established 'contrato de liquidez' (liquidity contract) for the period between February 25, 2025, and February 28, 2025. This type of disclosure, reporting on specific transactions like liquidity management or share buybacks/sales, is typically classified as a regulatory filing or a specific transaction report. Since the document explicitly details the results of transactions in own shares (buybacks/sales) under a liquidity agreement, it strongly aligns with the 'Transaction in Own Shares' (POS) definition, which covers share repurchase/issuance activities. Although it is a regulatory filing, POS is more specific than the general RNS fallback. The document is short and reports specific transactional data, not a full report, making POS the most accurate fit.
2025-04-04 Spanish
EthiFinance Ratings mantiene la calificación crediticia a largo plazo de Pharma Mar.
Interest Rate Update/Notice Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. It is dated April 4, 2025, and is titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The content explicitly states that the credit rating agency EthiFinance Ratings has maintained Pharma Mar, S.A.'s long-term credit rating at 'BB+' with a stable outlook. This type of announcement, which relays material, non-financial or non-periodic information to the regulator, fits best under the general category for regulatory announcements that don't match specific financial reports (like 10-K, ER, IR) or specific corporate actions (like DIV, DIRS). Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is very short (690 chars), suggesting it is an announcement rather than a full report.
2025-04-04 Spanish
La Comisión Ejecutiva de Pharma Mar, S.A. ha decidido la ejecución del Plan de Entrega de Acciones aprobado por acuerdo de su Junta General Ordinaria de fecha 29 de mayo de 2024.
Share Issue/Capital Change Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - Spanish Securities Market Commission) dated April 2, 2025. It announces a decision by the Executive Commission of Pharma Mar, S.A. regarding the execution of a share delivery plan for employees and executives, previously approved by the Shareholders' General Meeting. This plan involves the free delivery of up to 41,000 treasury shares, subject to vesting conditions (lock-up periods and termination clauses). This type of announcement, detailing the execution of a specific corporate action related to employee incentives and capital structure (share issuance/delivery), fits best under 'Capital/Financing Update' (CAP) or potentially 'Transaction in Own Shares' (POS) if the focus is purely on the treasury stock movement. However, since it details the execution of a pre-approved plan involving the transfer of shares to employees as an incentive, which is a form of capital management/financing activity, CAP is a strong candidate. Given the specific nature of delivering treasury shares to employees under an incentive plan, POS (Transaction in Own Shares) is also highly relevant as it describes the actual movement of shares. Since the core action is the delivery/transfer of shares from the company's treasury to employees, POS is the most precise fit among the options provided, as it covers share repurchase/issuance transactions, and this is an issuance to employees from treasury stock. It is not a general financing update (CAP) but a specific transaction type.
2025-04-02 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) made by a director ('CONSEJERA') of the issuer (PHARMA MAR, S.A.). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2025-04-02 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 24 de marzo y el 28 de marzo de 2025.
Transaction in Own Shares Classification · 100% confidence The document is a formal communication to the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores) dated March 31, 2025. The subject is "Programas de recompra de acciones, estabilización y autocartera" (Share repurchase programs, stabilization, and treasury stock). It details specific 'Compra' (Buy) operations conducted by Pharma Mar, S.A. during the period of March 24 to March 28, 2025, including the number of shares and weighted average price. This activity directly relates to the company buying back its own shares. According to the definitions, this corresponds precisely to the 'Transaction in Own Shares' category. Filing Code: POS (Transaction in Own Shares).
2025-03-31 Spanish
Sylentis, filial de Pharma Mar, recibirá 21,1 millones de euros del fondo NextGenerationEU para la investigación en enfermedades raras y la construcción de una planta.
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) under the heading 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It announces that Sylentis (a subsidiary of PharmaMar) has been selected to receive a €21.1 million grant from the European Commission under the IPCEI 'Med4Cure' program, funded by NextGenerationEU. The document explicitly states, 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia' (A press release that will be distributed to the media regarding this news is attached). This structure—a formal regulatory filing announcing news and attaching a press release—is characteristic of a general regulatory disclosure that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement to the regulator about a significant event (grant funding and industrial project), and it is not a specific financial report, the most appropriate general category is Regulatory Filings (RNS), as it serves as a catch-all for mandatory disclosures that aren't otherwise categorized. It is not an Earnings Release (ER) as it focuses on funding/R&D, nor is it a Capital/Financing Update (CAP) which usually relates to debt/equity issuance, although it involves funds. It is a direct regulatory disclosure.
2025-03-27 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.